Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232 by Diaconu, C-C et al.
Clinical resistance to chemotherapeutic drugs is an important
problem in the treatment of cancer. Tumour cells can acquire resis-
tance to a wide variety of unrelated cytotoxic drugs when they are
exposed to a chemotherapeutic agent. This phenomenon is called
multidrug resistance (MDR). The molecular basis of a major form
of MDR is the overexpression of P-glycoprotein (P-gp), which
functions as an adenosine 5¢-triphosphate (ATP)-dependent efflux
pump for several structurally and functionally unrelated cytotoxic
drugs (Endicott and Ling, 1989; Gottesmann, 1993). The
cirumvention of resistance to chemotherapy has become one of the
primary goals of modern approaches to cancer therapy.
Several chemotherapeutic drugs kill drug-sensitive cells by
apoptosis (Dyson et al, 1986; Muller et al, 1997). Physiological or
apoptotic cell death is an active, genetically programmed suicidal
process that consists of a cascade of well-regulated events with
the participation of specific genes (Wyllie et al, 1980; Sen and
D’Incalci, 1992). The three main stages of programmed cell
death are signalization, control and execution (Golstein, 1997).
Disturbance of any of these stages may result in the failure of the
apoptotic programme. Resistance to apoptosis has emerged as an
important category of treatment resistance (Fisher, 1994). Recent
research efforts have concentrated on the possibility of the manip-
ulation of apoptotic cell death in order to intervene therapeutically
in cancer, where failure or suppression of apoptosis is likely to
contribute both to the initial development of cancer and to the
appearance of tumour cells resistant to chemotherapy.
Somatostatin is a tetradecapeptide with diverse biological
effects on cellular functions, including the inhibition of secretory
and proliferative processes (Brazeau, 1973; Schally, 1988). These
effects are mediated by specific receptors that belong to the
guanine nucleotide binding protein-linked receptor family (Patel
et al, 1995).
In a search for tumour-selective somatostatin analogues, we
earlier found that one of our analogues, TT-232 (D-Phe-Cys-D-
Trp-Lys-Cys-Thr-NH2), exerted a strong antiproliferative effect,
but had practically no growth hormone release inhibitory or anti-
secretory activity (Kéri et al, 1993a, 1993b). This compound has a
substantially different structure from the growth hormone active
analogues (Jaspers et al, 1994). We have demonstrated that TT-232
exerts a strong in vitro and in vivo anti-tumour activity (Kéri et al,
1996).
The most frequent form of primary liver cancer is hepatocellular
carcinoma, which causes more than 300 000 deaths per year
(Ozturk, 1996). Hepatocellular carcinoma cells are essentially
refractory to chemotherapy. The aim of our recent work was to
examine whether TT-232 exerts antiproliferative effects on
hepatoma cells and whether apoptosis can be triggered in
hepatomas. An important part of this work was to test the antipro-
liferative effect of TT-232 on multidrug-resistant hepatoma cells.
We earlier isolated stable, heat-resistant rat hepatoma variants by
using repeated heating cycles at 45°C (Venetianer et al, 1994).
These heat-resistant variants became moderately multidrug-
resistant, they expressed a slightly elevated level of P-gp and an
increased basal level of several heat-shock proteins (Venetianer
et al, 1994; Pirity et al, 1996). Highly multidrug-resistant
hepatoma variants were also isolated with increasing concentra-
tions of colchicine, these cells strongly overexpressed functional
P-gp. Our closely related hepatoma variants representing different
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induce apoptosis in the different hepatoma cells.
MATERIALS AND METHODS
Cells lines, media, culture conditions
The culture conditions have been described elsewhere (Venetianer
et al, 1980). Briefly, the cells were grown in F12 (GibcoBRL)
medium supplemented with 5% fetal calf serum (BIO MEDIA) in
a humidified atmosphere of 8% carbon dioxide in air.
The glucocorticoid-resistant clone 2 cells (Venetianer et al,
1980) were isolated from the glucocorticoid-sensitive, differen-
tiated rat hepatoma Faza 967 clone (Deschatrette and Weiss,
1974). Clone 2 cells were grown for several years in the presence
of 2 mM dexamethasone, and lost the ability to express all liver-
specific functions examined, i.e. they became dedifferentiated
(Venetianer et al, 1983).
Stable heat-resistant cells of clone 2 were isolated by ten
repeated cycles of heat exposure at 45°C for 80 min. A subclone
derived from them and used in the present studies is referred to as
clone 2(10´80)T1 (Venetianer et al, 1994). The heat-resistant
derivatives of clone 2 cells were moderately multidrug-resistant.
The relative resistance of clone 2(10´80)T1, determined with
Trypan blue exclusion test after treatment for 72 h with various
concentrations of drugs was the following: 5.2 for vinblastine, 9.4
for doxorubicin, 11.4 for puromycin, 7.7 for actinomycin D and
2.4 for colchicine (Pirity et al, 1996).
The highly multidrug-resistant variants were isolated from
clone 2 cells (clone 2c1000) and from the moderately multidrug-
resistant clone 2(10´80)T1 (clone 2(10´80)T1c1000) by using step-
wise selection with colchicine, and thereafter grown continuously
in the presence of 1000 ng ml–1 colchicine. The relative resistance
of clone 2c1000 and clone 2(10´80)T1c1000 was found to be: 34 and
5.7 for vinblastine, 8.8 and 14.6 for doxorubicin, 65.9 and 65.6 for
puromycin, 21.3 and 36.3 for actinomycin D and 37.4 and 40.7 for
colchicine respectively (Pirity et al, 1996). The MDR of the vari-
ants correlated with the overexpression of the functional P-gp
(Pirity et al, 1996). The highly multidrug-resistant variants were
grown in the absence of colchicine for a week before performing
viability tests or other assays.
Cell viability tests
Equal numbers of cells were plated into 35-mm Petri dishes. One
day later, the cells were treated with different concentrations of
TT-232 and the numbers of viable cells were determined by the
Trypan blue exclusion test 24, 48 and 72 h later. For evaluation of
the results, it should be considered that in cultured cells the cell
membrane does not become permeable to vital dyes in the first and
second stages of apoptosis, but only in the third stage; as the
membranes rupture, the cells become permeable (Arends and
Willie, 1991).
XTT assay
Equal numbers of cells were plated into 96-well tissue culture
plates. One day later, the cells were treated with different concen-
trations of TT-232. Cell viability was determined in triplicate wells
for each drug concentration using the XTT/PMS viability dye
assay (Scudiero et al, 1988; Roehm et al, 1991) 24, 48 and 72 h
later. Cell viability was expressed as the per cent of absorbance of
treated cells relative to the untreated control wells, measured at
450 nm.
The concentrations of drugs which reduced the viability of the
treated cells by 50% of that of controls (IC50 values) were deter-
mined using the Trypan blue exclusion test and the XTT assay.
Colony-forming ability after drug exposure
Aliquots of about 1000 dispersed cells were seeded into Petri
dishes in triplicates and treated with drugs 16 h later (control cells
were not treated); culture media were renewed weekly. Clone
2(10´80)T1 and clone 2(10´80)T1c1000 cells were grown for 11
days, clone 2 and clone 2c1000 for 17 days, thereafter the plates were
fixed, stained and counted, as described previously (Venetianer et
al, 1978; Pirity et al, 1992).
Assay for induction of apoptosis
A total of 1 ´ 105 (for propidium iodide) or 5 ´ 104 (for cytospin)
cells were seeded in 35-mm Petri dishes with or without coverslips
and treated with different concentrations of TT-232 1 day later.
After exposure, cells seeded on coverslips were fixed, washed and
subsequently stained with propidium iodide as described earlier
(Bonfoco et al, 1995). Coverslips were examined either with a
Zeiss, Axiovert 135 M confocal laser scanning microscope or
with a Leitz fluorescence microscope. Nuclei of untreated cells
revealed a typical chromatin morphology with distinct organiza-
tion, whereas apoptotic nuclei were highly fluorescent, condensed
and displayed polarized chromatin aggregates. For quantitative
evaluation of apoptotic cells, 20 fields (at least 200 cells) were
counted in each preparation. In parallel, the percentage of cells
with morphological characteristics of apoptosis and necrosis was
determined on a May–Grünwald–Giemsa-stained cytospin prepa-
ration (Shandon Elliot cytocentrifuge) by counting at least 400
cells.
Confocal microscopy
Confocal microscopic studies were performed with a Zeiss,
Axiovert 135 M, LSM 410 Laser Scan Confocal Microscope and a
100´ (N.A. = 1.5, oil) objective. The z-axis position was fixed so
that the optical section clearly transected the nuclei. Fluorescence
was excited by using an argon ion laser at 488 nm (15 mW).
Nuclei area measurements for at least 20 randomly selected fields
of propidium iodide-stained TT-232-treated and control cells were
performed using the LSM software, which is based on the
Microsoft Windows graphical user interface.
DNA ladder assay
Clone 2 and clone 2(10´80)T1c1000 cells were treated with
30 mg ml–1 TT-232 for 21 h; control cells were not treated. As an
internal control for ladder formation, drug-sensitive clone 2 cells
were treated with 60 ng ml–1, highly drug-resistant clone
2(10´80)T1c1000 cells with 600 ng ml–1 actinomycin D for 21 h.
Fragmented DNA was separated from intact DNA, extracted and
loaded onto agarose gels as described earlier (Laurent-Crawford et
al, 1991). PstI-digested l DNA was used as molecular weight
marker.
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Hepatoma cells were exposed to 10 mM doxorubicin for 4 h, in the
presence or absence of 10 mg ml–1 TT-232. The intracellular
concentration of doxorubicin was determined as described previ-
ously (Fardel et al, 1993).
Peptides
TT-232 (D-Phe-Cys-Try-D-Trp-Lys-Cys-Thr-NH2) was synthe-
tized in our laboratory as described earlier (Kéri et al, 1993a) then,
2 mg ml–1 TT-232 stock solution was prepared by dissolving
TT-232 in 0.2 M acetic acid–sodium acetate buffer, pH 3.45
adjusted to 5% mannit (w/v) and stored at 4°C up to 1 month.
Before use the TT-232 stock solution was diluted in culture
medium. The vehicle was also added to control cultures.
Chemicals were obtained from Sigma.
RESULTS
In vitro antiproliferative effect of TT-232 on hepatoma
cell lines
XTT assay was used to compare the cytotoxicity of TT-232 on
different variants. Cells were treated with different concentrations
of TT-232 for 3 days. IC50 values determined at least in three inde-
pendent experiments were the following: 14 ± 1.8 mg ml–1 for
clone 2, 10 ± 0.7 mg ml–1 for clone 2(10´80)T1, 12 ± 1.1 mg ml–1
for clone 2(10´80)T1c1000 and 12 ± 1.5 for the drug-sensitive,
differentiated Faza 967. The effect of TT-232 on cell viability was
also determined using the Trypan blue exclusion test following a
1-day treatment. The IC50 were found to be between 45 and
54 mg ml–1 (54 ± 3 mg ml–1 for clone 2; 53 ± 4 mg ml–1 for clone
2c1000; 45 ± 3 mg ml–1 for clone 2(10´80)T1; 45 ± 4 mg ml–1 for
clone 2(10´80)T1c1000; and 46 ± 3 mg ml–1 for Faza 967 clone).
To examine the long-term effects of TT-232 on different
hepatomas, the cells were treated continuously up to 17 days with
the hormone analogue and the extents of colony formation were
compared. While 10 mg ml–1 TT-232 had no or only a slight effect
on colony formation, 15 mg ml–1 drastically inhibited colony
formation in all hepatoma variants (Figure 1).
The results of the different assays clearly show that TT-232
inhibits the proliferation and viability of all examined hepatoma
cells and the inhibition is dose- and time-dependent. These experi-
ments reveal that the sensitivity of moderately- and highly
multidrug-resistant variants to TT-232 was not reduced.
TT-232 induces apoptosis in drug-sensitive and
multidrug-resistant cells
In an attempt to characterize the mechanisms responsible for the
cytotoxicity of TT-232 on hepatoma cells, we tested the possible
apoptosis-inducing effect of the hormone analogue. Treatment
of hepatoma cells with TT-232 induced the typical apoptotic
morphology in both drug-sensitive (Figure 2A, B) and multidrug-
resistant cells (Figure 2C, D). To determine the ratio of apoptotic
and necrotic cells the variants were treated with TT-232 for 1, 2 and
3 days. The percentage of cells with morphological characteristics
of apoptosis was determined on coverslips following propidium
iodide staining and in May–Grünwald–Giemsa-stained cytospin
preparations. Necrosis occurred at much lower rates than apoptosis
in all TT-232-treated cells; 20 mg ml–1 TT-232 induced approxi-
mately 20–40% apoptosis and 9–12% necrosis after treatment for
1 day, 30–60% apoptosis and 3–17% necrosis after treatment for
2 days, and 40–70% apoptosis and 9–28% necrosis after treatment
for 3 days. Figure 2E, F depicts the percentages of apoptotic and
necrotic cells in clone 2, clone 2c1000 and clone 2(10´80)T1c1000 cells
following treatment with TT-232 for 3 days. It is clear from the
results that the MDR of hepatomas is not correlated with a reduced
susceptibility to apoptosis induction by TT-232.
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Figure 1 Colony formation of hepatoma variants in the presence or absence (c) of different concentrations of TT-2321200 C-C Diaconu et al
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Figure 2 TT-232 induces apoptosis in hepatoma variants. Morphological appearance of apoptotic cells. Drug-sensitive clone 2 (C) and multidrug-resistant
clone 2(10´80)T1c1000 (D) cells were treated with 40 mg ml–1 TT-232 for 1 day and stained with propidium iodide. Control cells (A, B) were not treated. Apoptotic
nuclei are highly fluorescent, condensed. Quantitation of apoptotic (E) and necrotic (F) cell death in hepatoma variants treated with 20 mg TT-232 for 72 h.
Apoptotic cells are expressed as a percentage of the total propidium iodide-stained cells attached to coverslips. The percentage of necrotic cells was
determined in May–Grunwald–Giemsa-stained cytospin preparations. Bars are the mean ± s.e.m. of the results of three experiments
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Clone 2(10x80)T1c1000 Clone 2 Clone 2c1000The apoptosis-inducing effect of TT-232 was also examined by
measuring the areas of propidium iodide-stained nuclei with LSM
software. During apoptosis, cell shrinkage and chromatin conden-
sation occurred. Treatment of the hepatoma cells with TT-232 for
1, 2 and 3 days resulted in clear decreases in the areas of the nuclei.
While the area of nuclei of the majority of control cells was around
300 mm2, it was much lower, with highest frequencies around
140 mm2, following treatment with 20 mg ml–1 TT-232 for 3 days
(Figure 3). A similar reduction in the size of the treated nuclei was
seen for the highly drug-resistant hepatoma clone 2c1000 (Figure 3).
To learn whether treatment with increasing concentrations of
TT-232 induces apoptosis in a dose-dependent manner, the drug-
sensitive and resistant cells were treated with different concentra-
tions of TT-232 for 1 day. The percentage of apoptotic cells
increased in all hepatomas with increasing concentration of
TT-232 and was between 60 and 75% at 60 mg ml–1 TT-232, while
the percentage of necrotic cells was significantly lower. These
results reveal that the apoptosis-inducing effect of TT-232 is dose
and time-dependent.
Induction of DNA fragmentation in response to TT-232
treatment
One of the earliest steps in apoptosis appears to be DNA digestion.
Apoptosis is usually associated with the activation of nucleases
that degrade the chromosomal DNA first into large, and subse-
quently into very small, oligonucleosomal fragments.
Clone 2 and the multidrug-resistant cells were treated with
30 mg ml–1 TT-232 for 21 h. For comparison, the cells were also
treated with actinomycin D, which induces apoptosis and DNA
ladder formation in these cells (unpublished results). A character-
istic pattern of DNA fragments was observed in both drug-
sensitive and resistant cells, which consisted of multimers of
approximately 180 base pairs. A typical DNA fragmentation
pattern is shown in Figure 4.
TT-232 is not a substrate of P-glycoprotein
We reported earlier that the overexpression of P-gp in both moder-
ately and highly multidrug-resistant hepatoma variants correlated
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Figure 3 Nuclear area distribution in clone 2 and clone 2c1000 cells following treatment with 20 mg ml–1 TT-232 for 1, 2 and 3 days. Nuclei area measurements
for at least 20 randomly selected fields were performed by using LSM software as described above. (A, C) Clone 2, clone 2c1000 control; (B, D) clone 2, clone
2c1000 treatedwith a decreased accumulation of anticancer drugs, such as
doxorubicin (Pirity et al, 1996). Addition of verapamil, a calcium
channel blocker drug known to reverse MDR by inhibiting P-gp
function, significantly increased the cellular doxorubicin accumu-
lation. Addition of TT-232, however, had no effect on the doxoru-
bicin retention. The intracellular concentration of doxorubicin in
the absence and presence of 10 mg ml–1 TT-232 was found to be:
38.5 ± 4 and 39.5 ± 4 mM mg–1 protein in clone 2, and 1.2 ± 0.1 and
1.3 ± 0.1 mM mg–1 in clone 2(10´80)T1c1000 cells), indicating that
TT-232 is not a substrate for P-gp.
DISCUSSION
A structural analogue of somatostatin (TT-232) has been devel-
oped in our laboratory. TT-232 has been tested on various human
tumour cell lines by the National Cancer Institute of NIH. It was
found that 100 mM of TT-232 had a strong antiproliferative effect
on the majority of cell lines. We recently reported that TT-232
induced apoptosis in different human tumour cell lines (Kéri et al,
1996). In vivo, TT-232 was effective on transplanted animal
tumours (COLO26, B16 melanoma and S180 sarcoma) and on
human tumour xenografts (Kéri et al, 1996). We found, for
example, that 30% of S180 tumour-bearing mice treated twice
daily intraperitonially with low dose (15 mg kg–1) of TT-232 for
12 days became tumour-free, while continuous administration of
the drug resulted in 60% tumour-free animals (Kéri et al, 1997).
Our data suggest that TT-232 is a promising anti-tumour agent.
Primary cancer of the liver is the fourth most common cause
of death from cancer (Ozturk, 1996). Hepatocellular carcinomas
generally do not respond well to chemotherapy. Numerous mecha-
nisms of drug resistance are well established for tumour cells in
vitro (Fisher, 1994). The main goal of cancer chemotherapy is to
kill tumour cells, but not their normal counterparts, with specific
antineoplastic drugs. One promising way for doing this is to
induce the genetically encoded death programme in cancer cells,
including the multidrug-resistant tumour cells.
In this report, we have demonstrated for the first time that
TT-232 has pronounced antiproliferative effects on hepatocellular
carcinoma cell lines, including differentiated and dedifferentiated,
drug-sensitive and multidrug-resistant hepatomas. Long-term
treatment of the hepatomas with 15 m ml–1 TT-232 drastically
inhibited colony formation in all examined hepatoma variants. The
IC50 values determined by the Trypan blue exclusion test were in
the range 40–50 mM, indicating comparable sensitivities of the
variants. The IC50 values for breast, colon and prostate lines were
in the range 20–40 mM (Kéri et al, 1996).
The most important finding in our experiments was that TT-232
induces apoptosis in all examined hepatoma variants. Treatments
of hepatoma cells with TT-232 induced a typical apoptotic
morphology, with a clear decrease in the areas of the nuclei and a
characteristic pattern of DNA fragmentation. The major form of
cell death occurring in the different hepatoma variants was
apoptosis. The percentages of apoptotic cells were comparable
following treatment with TT-232 in the drug-sensitive and highly
multidrug-resistant hepatomas. Multidrug-resistant hepatoma
variants overexpressing functional P-gp were found not to be less
sensitive to TT-232 than the P-gp non-expressing, drug-sensitive
cells. These observations can be explained by our observations
showing that TT-232 is not a substrate of P-gp. These results
clearly reveal that the machinery involved in apoptosis is func-
tional both in drug-sensitive and in drug-resistant hepatoma vari-
ants, and it can be activated by the somatostatin analogue TT-232.
Our earlier results showed that the basal expression of several
heat-shock proteins was increased in the heat-resistant, moderately
multidrug-resistant hepatoma variants and in the highly multidrug-
resistant derivatives of them (Venetianer et al, 1994; Pirity et al,
1996). Heat-shock proteins play an important role in protecting
cells from the harmful effects of stress (Morimoto et al, 1990) and
could also protect cells from apoptotic cell death (Mosser et al,
1992; Mehlen et al, 1996). Our data presented in this paper indi-
cate that the observed increased basal expression of Hsp27 and
Hsp70 did not prevent the initiation of apoptotic pathway in
hepatoma cells treated with TT-232.
In recent years, considerable effort has been directed towards the
development of small molecular tyrosine kinase inhibitors as
potential anti-tumour drugs (Levitzki and Gazit, 1995). It was
demonstrated that somatostatin and other pepide hormones and
analogues, which inhibit tyrosine kinase activity, can also induce
apoptosis (Kéri et al, 1996). Although we could not measure the
inhibitory effect of TT-232 on the tyrosine kinase activity of our
hepatoma cells, due to the low basal activity of the enzyme, we
observed that the apoptosis-inducing effect of a recently described,
very potent tyrosine kinase inhibitor, which is a quinazoline deriva-
tive (PD153035; Fry et al, 1994), on multidrug-resistant hepatoma
cells is comparable to that of TT-232 (unpublished results).
Our recent finding showing that TT-232 can kill not only
hepatocellular carcinoma cells, but also the multidrug-resistant
variants by apoptosis together with our earlier data demonstrating
strong in vivo anti-tumour activity at relatively low doses, and the
results of toxicity studies suggest that TT-232 is a promising anti-
tumour agent.
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Figure 4 DNA fragmentation in TT-232-treated hepatoma cells. Clone 2
cells were treated with 60 ng ml–1 actinomycin D (lane 3), with 30 mg ml–1 TT-
232 (lane 4) for 21 h, control cells (lane 2) were untreated. Clone 2(10´80)
T1c1000 cells were treated with 600 ng ml–1 actinomycin D (lane 8), with
30 mg ml–1 TT-232 (lane 9) for 21 h, control cells were untreated (lane 7).
Lanes 1, 6: g HindIII; lanes 5,10: g DNA/Pst 1. Fragmented DNA was
separated from nucleoplasm, extracted and loaded onto agarose gels
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